Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sosei
Biotech
Boehringer pays €25M for option to Sosei’s schizophrenia drug
Boehringer has secured an opportunity to beef up its schizophrenia portfolio courtesy of a €25 million ($27.3 million) deal with Sosei Heptares.
James Waldron
Mar 11, 2024 9:10am
GSK jilts Sosei, axing bowel disease drug amid immunology pivot
Nov 27, 2023 5:00am
Lilly pens $730M deal with Sosei Heptares to push GPCRs
Dec 16, 2022 7:35am
AbbVie pays Sosei $40M to form neurological drug discovery pact
Aug 2, 2022 7:00am
Neurocrine pens $2.6B biobucks pact with Sosei Heptares
Nov 22, 2021 9:15am
AstraZeneca scraps midphase drugs from $1B buyout, Heptares pact
Nov 12, 2021 7:30am
